Zhejiang funding needs a ready partner and a cash-flow plan

Original research record

We see a partnership-readiness test behind the Singapore–Zhejiang innovation deadline. Singapore applications close on 9 October 2026 at 17:30 SGT, but the call also needs an independent Zhejiang partner, agreed work and a plan to fund costs before reimbursement. Results are tentatively due in April 2027; payment timing is not established.

We connected the latest OTR Database Data opportunity briefing with Enterprise Singapore’s programme page and current fifth-call document. The Singapore submission deadline is 9 October at 17:30 SGT. The correct route is EDG (Co-Innovation Programme) through BGP2.0; Enterprise Singapore says this is separate from ordinary EDG. [Programme](https://www.enterprisesg.gov.sg/grow-your-business/innovate-with-us/market-access-and-networks/global-innovation-alliance/cip/singapore-china-yrd-zhejiang-joint-innovation-call)

The current rules add the key cash-flow point: support is by reimbursement. Approval requires both Singapore and Zhejiang agencies, with approved projects tentatively announced in April 2027. We infer that teams need a ready collaboration and financing plan, not just an idea submitted before the clock runs out. [Call rules](https://www.enterprisesg.gov.sg/-/media/esg/files/financial-assistance/grants/for-local-companies/international-co-innovation-programmes/singapore-zhejiang-joint-innovation-call/call-document-for-5th-sg-china-yrd-zhejiang-joint-innovation-call.pdf)

Two different 70% limits apply. Each partner’s contribution is capped at 70% of total project budget and person-months; Singapore support may cover up to 70% of qualifying costs. Neither promises full funding. The Singapore company must operate locally, have at least 30% local equity and be financially able to finish. At least one independent company in each location must participate. The application needs a signed MOU, letter of intent or collaboration agreement. Partners should agree on intellectual property and commercialisation before applying. The Jiangsu page gives 12 October at 17:30 SGT but also says applications are currently closed. We would confirm its status with Enterprise Singapore before treating it as a fallback.

These calls can help a team that already has the right partner and documents. Missing partner eligibility, weak project finances or failure to win either agency’s approval could stop funding. An extension or corrected programme notice could change timing. We have not checked any applicant’s eligibility or entered the application portal, and we have not verified the Zhejiang-side deadline.

We would check the partner agreement, financing and exact programme route before spending effort on a last-minute submission. The stated grant ceiling is potential support after approval, not cash already available.

This signal has no investible bullish or bearish call. A market-direction percentage does not apply. Bayesian · what changed the estimate? The detailed rules add financial and partnership conditions to the deadline in the research briefing. We would update our view if the agency changes those conditions. No fitted approval model or numerical posterior is available. de Finetti · are the comparisons fair? The programme webpage and its attached rules share one issuing agency and one call. They do not count as two successful cases. Zhejiang and Jiangsu have different partners and rules, so one cannot stand in for the other. Kolmogorov · do the numbers agree? A contribution share and a reimbursement rate have different denominators. They cannot be added or treated as approval probabilities. We issue no numerical forecast; bullish, bearish, neutral and a market price band are not applicable. Horizon, price basis and market neutral band: Not applicable. We issue no numerical forecast. Read the shared method: https://new.ontherice.org/how-otr-works/#probability-framework.

Evidence behind this view We read the OTR Database Data briefing first, then checked the current Enterprise Singapore page and its linked 2026 call rules. They describe one programme and are not independent reports of success. The Jiangsu page is a separate call with a visible status conflict. [Zhejiang](https://www.enterprisesg.gov.sg/grow-your-business/innovate-with-us/market-access-and-networks/global-innovation-alliance/cip/singapore-china-yrd-zhejiang-joint-innovation-call) [Rules](https://www.enterprisesg.gov.sg/-/media/esg/files/financial-assistance/grants/for-local-companies/international-co-innovation-programmes/singapore-zhejiang-joint-innovation-call/call-document-for-5th-sg-china-yrd-zhejiang-joint-innovation-call.pdf) [Jiangsu](https://www.enterprisesg.gov.sg/grow-your-business/innovate-with-us/market-access-and-networks/global-innovation-alliance/cip/singapore-china-yrd-jiangsu-joint-innovation-call)

What past price moves show Market-price moves do not apply. We found no comparable set of grant approvals, disbursement timings or completed joint projects for this call. We cannot estimate approval odds or a typical cash delay.

Evidence against this view The close deadline may be useful mainly to teams that already have an eligible partner and complete paperwork. The April 2027 result timing is tentative. The neighbouring Jiangsu listing cannot be assumed open while its own wording conflicts.

Why the direction changed No investment direction is issued or changed. The deadline was already scheduled before this research. Our new synthesis links the imminent submission step to partnership balance, dual approval and reimbursement. It does not describe the grant as newly created.

What people say vs the facts We did not verify an applicant or social-media sample. An opportunity listing gives conditions, not proof that companies can meet them. We do not infer strong take-up or successful commercial products.

How past forecasts performed We have no matched, resolved outcome sample and give no approval probability or claimed hit rate. Submission, joint approval, reimbursement and product sales are different outcomes that should be recorded separately.